Common CMC Strategy Failures That Drive Cost Overruns and Rework Common CMC Strategy Failures That Drive Cost Overruns and Rework In today’s dynamic pharmaceutical and biotechnology environment, a well-defined Chemistry, Manufacturing, and Controls (CMC) strategy is critical for success. Issues in CMC can lead to significant cost overruns and rework, impacting not only the financial bottom line but also timelines for product development and regulatory approval. This article provides a comprehensive analysis of common pitfalls in the CMC strategy lifecycle, detailing relevant regulations, agency expectations, and practical approaches to enhance alignment through risk-based planning and global CMC development. Regulatory Context…

Templates for CMC strategy playbooks by modality and product type Templates for CMC Strategy Playbooks by Modality and Product Type Context In the realm of pharmaceutical and biotechnology development, the Chemistry, Manufacturing, and Controls (CMC) strategy lifecycle is a fundamental aspect that dictates the course of product development from preclinical phases through to commercial marketing. Establishing a coherent CMC strategy is essential not just for regulatory compliance but also for the holistic integration of development efforts across various disciplines, including Clinical, Quality Assurance (QA), Pharmacovigilance (PV), and Commercialization. This article aims to provide a detailed regulatory explainer manual for crafting…

Global CMC Strategy Alignment Across FDA, EMA and Other Agencies Global CMC Strategy Alignment Across FDA, EMA and Other Agencies In the complex landscape of pharmaceutical and biotech product development, maintaining a robust Chemistry, Manufacturing, and Controls (CMC) strategy throughout the entire product lifecycle is critical. This article serves as a comprehensive regulatory explainer manual, outlining key considerations for aligning CMC strategies across global regulatory agencies, including the FDA, EMA, and MHRA. Context of Regulatory Affairs in CMC Strategy Lifecycle The CMC strategy lifecycle involves several stages—from early development through to commercialization—and necessitates a proactive approach to meet regulatory expectations….

Scenario planning in CMC strategy for capacity, sites and risk events Scenario Planning in CMC Strategy for Capacity, Sites and Risk Events Effective management of Chemistry, Manufacturing, and Controls (CMC) is critical throughout the product lifecycle, from early development to commercialization. This document provides a regulatory explainer manual on scenario planning in CMC strategy, focusing on capacity, sites, and risk events. This guide aims to align with FDA, EMA, MHRA expectations and provide actionable insights for Kharma and regulatory professionals. Context As pharmaceuticals and biotechnology companies navigate the complexities of CMC strategy, scenario planning is essential for anticipating capacity needs,…

Metrics and KPIs to Track Execution of Your CMC Lifecycle Strategy Metrics and KPIs to Track Execution of Your CMC Lifecycle Strategy In the global pharmaceutical and biotechnology landscape, an effective Chemistry, Manufacturing, and Controls (CMC) strategy lifecycle is critical for regulatory success and product commercialization. Regulatory Affairs (RA) professionals must understand the various metrics and key performance indicators (KPIs) that track CMC strategy execution from early development through to commercialization. This article serves as an exhaustive guide to the regulatory expectations and documentation practices, providing insights into the integration of CMC with Clinical, Pharmacovigilance (PV), Quality Assurance (QA), and…

Incorporating Device and Packaging Considerations into CMC Planning Incorporating Device and Packaging Considerations into CMC Planning The complexity of the pharmaceutical and biotechnology industries necessitates a comprehensive understanding of Chemistry, Manufacturing, and Controls (CMC) lifecycle management. This article aims to elucidate the critical intersection of device and packaging considerations within CMC strategy from early development to commercialization. Professionals in Regulatory Affairs (RA), Quality Assurance (QA), and related fields will benefit from a structured overview of relevant regulations, guidelines, and agency expectations across major jurisdictions, including the US, UK, and EU. Context Incorporating device and packaging considerations is imperative for a…

Building a Science-Based Control Strategy Around CQAs and CPPs Building a Science-Based Control Strategy Around Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) In the ever-evolving landscape of regulatory affairs, a robust CMC (Chemistry, Manufacturing and Controls) control strategy is imperative for ensuring the quality, safety, and efficacy of pharmaceutical products. This article serves as a comprehensive guide for regulatory professionals, particularly those in the pharmaceutical and biotech industries, on how to construct an effective control strategy centered on Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs). Context The regulatory frameworks in the US (FDA), EU (EMA), and…

How to define CQAs and CPPs using QbD principles and risk tools How to Define Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) Using QbD Principles and Risk Tools Regulatory Affairs Context In the pharmaceutical and biotech industries, establishing a robust Control Strategy is paramount for ensuring the consistent quality of products throughout their lifecycle. Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) form the core of this strategy, particularly when applying Quality by Design (QbD) principles. Understanding and defining CQAs and CPPs not only ensures compliance with regulatory expectations but also enhances the overall quality of the…

Translating development data into a commercial control strategy narrative Translating Development Data into a Commercial Control Strategy Narrative Regulatory Affairs Context The landscape of regulatory affairs (RA) within pharmaceutical and biotechnology industries continually evolves due to advancing scientific knowledge and changing regulations. A critical area of focus is the development and implementation of a Control Strategy (CS), which is essential for ensuring the quality of drug products throughout their lifecycle. This article covers the regulatory expectations and best practices for translating development data into a robust commercial control strategy narrative. Legal and Regulatory Basis In the US, the regulatory framework…

Control strategy expectations in Module 3 for FDA and EMA reviewers Control strategy expectations in Module 3 for FDA and EMA reviewers Regulatory Affairs Context In the pharmaceutical and biotech industries, the concept of control strategy is a critical component necessary for ensuring product quality and patient safety. Control strategies are integral in the development of pharmaceutical products, guiding decisions related to manufacturing processes, formulation, and quality assurance. Regulatory Affairs (RA) professionals must navigate the intricacies of control strategy formulation compliant with both FDA and EMA requirements. This article provides a comprehensive overview of the regulatory expectations for control strategies,…